Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 EV-to-EBITDA is 7.97 as of Jul. 14, 2026, which is 24% above its 10-year median of 6.41. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 739 Drug Manufacturers companies, Labiana Health ranks better than 72.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Labiana Health's enterprise value is €86.88 Mil.
Labiana Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €10.90 Mil. Therefore, Labiana Health's EV-to-EBITDA for today is 7.97.
The historical rank and industry rank for Labiana Health's EV-to-EBITDA or its related term are showing as below:
XMAD:LAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.05 Med: 6.41 Max: 19.7
Current: 7.97
During the past 6 years, the highest EV-to-EBITDA of Labiana Health was 19.70. The lowest was -67.05. And the median was 6.41.
XMAD:LAB's EV-to-EBITDA is ranked better than 72.26% of 739
companies
in the Drug Manufacturers industry
Industry Median: 12.98
vs XMAD:LAB: 7.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Labiana Health (XMAD:LAB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Labiana Health's PE Ratio (TTM) for today is calculated as:
Labiana Health's share price for today is €6.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.352.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Labiana Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:LAB vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Labiana Health's EV-to-EBITDA falls into.
Labiana Health's current Enterprise Value is €86.88 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Labiana Health's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €10.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a EV-to-EBITDA of 7.97 as of Jul. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Labiana Health. This is 24% above median its historical median of 6.41. According to the industry distribution chart, Labiana Health ranks #205 out of 739 companies in the Drug Manufacturers industry, placing it in the top 27.7%.
Is Labiana Health's EV-to-EBITDA too high?
Labiana Health's current EV-to-EBITDA of 7.97 is 24% above median its 10-year median of 6.41. The Drug Manufacturers industry median EV-to-EBITDA is 12.98. Labiana Health's value of 7.97 is 38.6% below this industry median. Based on the distribution chart, Labiana Health ranks #205 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #205 out of 739 companies for EV-to-EBITDA. This puts Labiana Health in the upper half of its industry. The industry median EV-to-EBITDA is 12.98. Labiana Health's value of 7.97 is 38.6% below this benchmark. While the company's 10-year median is 6.41 vs. the industry median of 12.98, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.98, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current EV-to-EBITDA of 7.97 is 38.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Labiana Health. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current EV-to-EBITDA is 7.97, which is 24% above median its own 10-year median of 6.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.65 — trading 85.2% above its estimated fair value. The current EV-to-EBITDA is 7.97, which is 24% above median its 10-year median of 6.41 and 38.6% below the Drug Manufacturers industry median of 12.98. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current EV-to-EBITDA is 7.97 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.65 is trading 85.2% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
EV-to-EBITDA: 7.97 (24% above median its 10-year median of 6.41)
GF Value™: €3.59 vs. price of €6.65 (85.2% above fair value)
Industry Position: 38.6% below the Drug Manufacturers median (#205 of 739)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
